On December 14, Zhejiang Zouli Pharmaceutical Co., Ltd. issued an announcement stating that its board of directors had approved the "Proposal on Purchasing an Asset Group and Signing an Acquisition Agreement." The company plans to acquire a group of trace element injections held by Tibet Future Biomedical Co., Ltd. and its two wholly-owned subsidiaries for a total price (including tax) of RMB 356 million. This asset group covers core assets such as R&D and production technology data, marketing authorizations, trademarks, and patents related to the marketed "Multiple Trace Element Injection (I)" and "Multiple Trace Element Injection (II)," as well as the research and development "Multiple Trace Element Injection (III)" under development.
The announcement indicates that multi-trace element injections are a major source of trace elements in parenteral nutrition, especially suitable for nutritional supplementation in special populations such as children and critically ill patients. Among them, multi-trace element injection (I) and multi-trace element injection (II) are both Class B drugs covered by national medical insurance and are products procured through inter-provincial centralized procurement. They have been recommended by multiple clinical guidelines and expert consensus documents and are widely used in clinical departments.
According to data from Moshang Pharmaceuticals (formerly Rongyun Pharmaceuticals) – a company with comprehensive hospital sales data – the overall market size for multi-trace element injections reached approximately RMB 1.8 billion in 2024. The market for multi-trace element injections is expected to continue its growth trend, particularly in the areas of pediatric nutritional support and adult critical care nutrition. In the future, with the launch of new products, increased market education, and greater patient acceptance, the market size is expected to expand further.
The company stated that this acquisition is an important step in completing its "all-age coverage" strategic puzzle . For many years, the company has focused on medicinal fungal bio-fermentation technology, and its core products, such as Wuling Capsules and Bailin Tablets, have established a solid advantage in the fields of adult nervous system, respiratory system, and urinary system. This acquisition, which provides access to the only pediatric multi-trace element injection (I) and an adult multi-trace element injection (II), will fill the gap in the company's pediatric treatment field, while extending its product line to key scenarios such as nutritional support for children and the elderly. It will also help the company build a "all-age coverage" health product and service chain spanning "children—adults—the elderly," fully focusing on disease treatment and health management for women, children, and the elderly within the context of the current national health development strategy.
It is reported that Future Pharma's multi-trace element injection has been selected in the centralized volume-based procurement of drugs by the Beijing-Tianjin-Hebei "3+N" alliance, the centralized volume-based procurement of drugs continuing after the expiration of the Hebei Provincial Alliance (Province) centralized procurement, and the Guangdong Alliance's continued centralized volume-based procurement. More than 20 provinces, including Zhejiang, Guangdong, and Anhui, have already implemented it. The multi-trace element injection (III), as an investigational product, completed its marketing application on February 27, 2025 (acceptance number: CYHS2500882) and is currently in the technical review stage.
Following this acquisition, the company is expected to leverage its existing marketing system and the complementary strengths of the asset group to drive development. The various trace element injections have a solid market foundation, and the company's existing centralized procurement bidding qualifications will facilitate product access. Simultaneously, the company possesses market advantages in centralized procurement and essential drug products, and can fully utilize its clinical promotion experience focused on "multi-departmental and evidence-based approaches" to achieve synergistic development with the various trace element injection product portfolio, better meeting the growing and diversified clinical needs.
It is understood that Future Pharma's Multi-Trace Element Injection (I) and Multi-Trace Element Injection (II) have been promoted and applied for many years and have been used in many hospitals. According to the "Pro forma Audit Report" issued by Zhonghui Accountants, the asset group achieved a net profit of RMB 45.7892 million from January to September 2025. After the completion of this acquisition, the company's profitability will be enhanced and its market competitiveness will be improved.

https://stcn.com/article/detail/3539535.html